{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:51:52Z","timestamp":1787313112479,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40268-024-00481-7","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T12:04:46Z","timestamp":1724155486000},"page":"359-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review"],"prefix":"10.1007","volume":"24","author":[{"given":"Mark T.","family":"Reding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadan","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ducore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Solms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l Andr\u00e9","family":"Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"7","key":"481_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/2040620718777903","volume":"9","author":"JN Mahlangu","year":"2018","unstructured":"Mahlangu JN, et al. BAY 81\u20138973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review. Ther Adv Hematol. 2018;9(7):191\u2013205.","journal-title":"Ther Adv Hematol."},{"key":"481_CR2","unstructured":"Centers for Disease Control and Prevention (CDC). Hemophilia Homepage. 2018. Available at: https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/facts.html. Accessed 9 Jul 2024"},{"issue":"7","key":"481_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd.2018.70","volume":"17","author":"R Peters","year":"2018","unstructured":"Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov. 2018;17(7):493\u2013508.","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 6","key":"481_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"key":"481_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S103796","volume":"8","author":"K Lieuw","year":"2017","unstructured":"Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017;8:67\u201373.","journal-title":"J Blood Med"},{"issue":"2","key":"481_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1586\/17474086.2015.1002465","volume":"8","author":"P Petrini","year":"2015","unstructured":"Petrini P, et al. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237\u201346.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"481_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","volume":"116","author":"B Mei","year":"2010","unstructured":"Mei B, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270\u20139.","journal-title":"Blood"},{"key":"481_CR8","unstructured":"European Medicines Agency. Jivi, INN- damoctocog alfa pegol. 2020 [cited 2021 July]; Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jivi-epar-product-information_en.pdf. Accessed 9 Jul 2024"},{"key":"481_CR9","unstructured":"US Food and Drug Administration. JIVI Package Insert. 2021 [cited 2021 Jul]; Available at: https:\/\/www.fda.gov\/files\/vaccines,%20blood%20%26%20biologics\/published\/Package-Insert-JIVI.pdf. Accessed 9 Jul 2024"},{"key":"481_CR10","unstructured":"Government of Canada Regulatory decision summary - Jivi - Health Canada. 2018."},{"key":"481_CR11","unstructured":"Pharmaceuticals and Medical Devices Agency Review report (Jivi, Damoctocog alfa pegol). 2018."},{"key":"481_CR12","doi-asserted-by":"crossref","unstructured":"Reding MT, et al. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia. 2021;27:e347\u2013e356.","DOI":"10.1111\/hae.14297"},{"issue":"3","key":"481_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.13597","volume":"15","author":"MT Reding","year":"2017","unstructured":"Reding MT, et al. Safety and efficacy of BAY 94\u20139027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017;15(3):411\u20139.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"481_CR14","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1111\/hae.13963","volume":"26","author":"E Santagostino","year":"2020","unstructured":"Santagostino E, et al. PROTECT VIII Kids: BAY 94\u20139027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia. 2020;26(3):e55\u201365.","journal-title":"Haemophilia"},{"key":"481_CR15","doi-asserted-by":"crossref","unstructured":"Mancuso, M.E., et al. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A. Haemophilia. 2021;27:434\u2013444.","DOI":"10.1111\/hae.14294"},{"issue":"2","key":"481_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000488060","volume":"45","author":"L Graf","year":"2018","unstructured":"Graf L. Extended half-life factor VIII and factor IX preparations. Transfusion Med Hemother. 2018;45(2):86\u201391.","journal-title":"Transfusion Med Hemother"},{"issue":"13","key":"481_CR17","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2011-08-367813","volume":"119","author":"JA Dumont","year":"2012","unstructured":"Dumont JA, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012;119(13):3024\u201330.","journal-title":"Blood"},{"issue":"1","key":"481_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2516.2012.02931.x","volume":"19","author":"IA Ivens","year":"2013","unstructured":"Ivens IA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19(1):11\u201320.","journal-title":"Haemophilia"},{"issue":"2","key":"481_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-2141.2002.03793.x","volume":"119","author":"EL Saenko","year":"2002","unstructured":"Saenko EL, et al. Factor VIII\u2014novel insights into form and function. Br J Haematol. 2002;119(2):323\u201331.","journal-title":"Br J Haematol"},{"issue":"2","key":"481_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102341","volume":"8","author":"KS Walsh","year":"2024","unstructured":"Walsh KS, et al. Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years. Res Pract Thromb Haemost. 2024;8(2): 102341.","journal-title":"Res Pract Thromb Haemost"},{"key":"481_CR21","unstructured":"Whetstone, P., et al. BAY 94-9027: a long-acting, site-specifically PEGylated, B-domain\u2013deleted recombinant factor VIII product of high and consistent purity for prolonged protection in patients with hemophilia A. In: THSNA. 2018."},{"issue":"10","key":"481_CR22","doi-asserted-by":"publisher","first-page":"25831","DOI":"10.3390\/ijms161025831","volume":"16","author":"JK Dozier","year":"2015","unstructured":"Dozier JK, Distefano MD. Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci. 2015;16(10):25831\u201364.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"481_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/hae.13564","volume":"24","author":"N Church","year":"2018","unstructured":"Church N, et al. Factor VIII activity of BAY 94\u20139027 is accurately measured with most commonly used assays: Results from an international laboratory study. Haemophilia. 2018;24(5):823\u201332.","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"481_CR24","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2019-125491","volume":"134","author":"P Meijer","year":"2019","unstructured":"Meijer P, et al. Inter-Laboratory Evaluation of the Recovery of Bay 94\u20139027 [Jivi\u00ae] with One-Stage Clotting and Chromogenic Assays. Blood. 2019;134(Supplement 1):1124.","journal-title":"Blood"},{"issue":"5","key":"481_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/0192623319852300","volume":"47","author":"IA Ivens","year":"2019","unstructured":"Ivens IA, et al. Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94\u20139027) With a 60 kDa PEG. Toxicol Pathol. 2019;47(5):585\u201397.","journal-title":"Toxicol Pathol"},{"key":"481_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejps.2019.01.015","volume":"130","author":"A Baumann","year":"2019","unstructured":"Baumann A, et al. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94\u20139027 in rats and its value for human prediction. Eur J Pharm Sci. 2019;130:11\u201320.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"481_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jth.12506","volume":"12","author":"TE Coyle","year":"2014","unstructured":"Coyle TE, et al. Phase I study of BAY 94\u20139027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12(4):488\u201396.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"481_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/hae.13561","volume":"24","author":"A Shah","year":"2018","unstructured":"Shah A, et al. BAY 94\u20139027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies. Haemophilia. 2018;24(5):733\u201340.","journal-title":"Haemophilia"},{"key":"481_CR29","unstructured":"US Food and Drug Administration. Adynovate (antihemophilic factor [recombinant], pegylated). Full Prescribing Information; Shire, Westlake Village, CA. 2017. Available at: https:\/\/www.drugs.com\/pro\/adynovate.html#s-34090-1. Accessed 9 Jul 2024"},{"key":"481_CR30","unstructured":"US Food and Drug Administration. Eloctate (antihemophilic factor [recombinant], Fc fusion protein). Full Prescribing Information, Bioverativ, Cambridge, MA. 2017. Available at: https:\/\/www.drugs.com\/pro\/eloctate.html. Accessed 9 Jul 2024"},{"issue":"1","key":"481_CR31","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1111\/hae.12294","volume":"20","author":"S Lalezari","year":"2014","unstructured":"Lalezari S, et al. Correlation between endogenous VWF: Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia. 2014;20(1):e15-22.","journal-title":"Haemophilia"},{"issue":"9","key":"481_CR32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","volume":"126","author":"BA Konkle","year":"2015","unstructured":"Konkle BA, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078\u201385.","journal-title":"Blood"},{"issue":"13","key":"481_CR33","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","volume":"119","author":"JS Powell","year":"2012","unstructured":"Powell JS, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031\u20137.","journal-title":"Blood"},{"issue":"5","key":"481_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/hae.12952","volume":"22","author":"K Saxena","year":"2016","unstructured":"Saxena K, et al. Efficacy and safety of BAY 81\u20138973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22(5):706\u201312.","journal-title":"Haemophilia"},{"key":"481_CR35","doi-asserted-by":"publisher","unstructured":"Solms A, Delesen H, Maas Enriquez M, Kenet G, Lalezari S. Intra\u2010individual across\u2010study comparison of pharmacokinetics of rFVIII\u2010FS, bay 81\u20108973 and bay 94\u20109027 in patients with severe haemophilia A (P043 EAHAD 2020). Haemophilia. 2020;26. https:\/\/doi.org\/10.1111\/hae.13911","DOI":"10.1111\/hae.13911"},{"issue":"9","key":"481_CR36","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00277-019-03747-2","volume":"98","author":"A Shah","year":"2019","unstructured":"Shah A, et al. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2019;98(9):2035\u201344.","journal-title":"Ann Hematol"},{"issue":"11","key":"481_CR37","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","volume":"99","author":"A Solms","year":"2020","unstructured":"Solms A, et al. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2020;99(11):2689\u201398.","journal-title":"Ann Hematol"},{"issue":"9","key":"481_CR38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40262-016-0492-2","volume":"56","author":"A Shah","year":"2017","unstructured":"Shah A, et al. Improved pharmacokinetics with BAY 81\u20138973 versus antihemophilic factor (Recombinant) plasma\/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A. Clin Pharmacokinet. 2017;56(9):1045\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"481_CR39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40262-019-00832-7","volume":"59","author":"A Solms","year":"2020","unstructured":"Solms A, et al. Favorable pharmacokinetic characteristics of extended-half-life recombinant factor VIII BAY 94\u20139027 enable robust individual profiling using a population pharmacokinetic approach. Clin Pharmacokinet. 2020;59(5):605\u201316.","journal-title":"Clin Pharmacokinet"},{"key":"481_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852","volume":"50","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, et al. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Rev. 2021;50: 100852.","journal-title":"Blood Rev"},{"issue":"2","key":"481_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/hae.14960","volume":"30","author":"D Matino","year":"2024","unstructured":"Matino D, et al. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A >\/= 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia. 2024;30(2):345\u201354.","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"481_CR42","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2018-99-116031","volume":"132","author":"E Santagostino","year":"2018","unstructured":"Santagostino E, et al. Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94\u20139027) Study. Blood. 2018;132(Supplement 1):2486\u20132486.","journal-title":"Blood"},{"issue":"S2","key":"481_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13786","volume":"25","author":"TRM Liu","year":"2019","unstructured":"Liu TRM, et al. Bleeding Outcomes During the Last 90 Days of Treatment with BAY 94\u20139027: Results From a Post-hoc Analysis of the PROTECT VIII Study. Haemophilia. 2019;25(S2):3\u201377.","journal-title":"Haemophilia"},{"key":"481_CR44","doi-asserted-by":"crossref","unstructured":"Reding, M.T., et al. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. 2020. 26(1365-2516 (Electronic)):3.","DOI":"10.1111\/hae.13982"},{"issue":"S2","key":"481_CR45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14236","volume":"27","author":"ME Mancuso","year":"2021","unstructured":"Mancuso ME, et al. Efficacy and safety of Bay 94\u20139027 prophylaxis is sustained for \u2265 6 years: Outcomes in 22 patients in the PROTECT VIII extension study. Haemophilia. 2021;27(S2):18\u2013181.","journal-title":"Haemophilia"},{"key":"481_CR46","doi-asserted-by":"publisher","first-page":"204062072311667","DOI":"10.1177\/20406207231166779","volume":"14","author":"MT Reding","year":"2023","unstructured":"Reding MT, et al. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients \u2a7e40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study. Ther Adv Hematol. 2023;14:20406207231166780.","journal-title":"Ther Adv Hematol"},{"key":"481_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.thromres.2019.08.023","volume":"183","author":"E Santagostino","year":"2019","unstructured":"Santagostino E, et al. Safety and efficacy of BAY 94\u20139027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: results of the PROTECT VIII clinical trial. Thromb Res. 2019;183:13\u20139.","journal-title":"Thromb Res"},{"key":"481_CR48","doi-asserted-by":"crossref","unstructured":"Santagostino E. et al. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Haemophilia (under review). 2021;27:e559\u2013e562.","DOI":"10.1111\/hae.14319"},{"issue":"6","key":"481_CR49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40271-019-00374-x","volume":"12","author":"JR Wells","year":"2019","unstructured":"Wells JR, et al. Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94\u20139027 extension studies (PROTECT VIII). Patient. 2019;12(6):611\u20139.","journal-title":"Patient"},{"issue":"6","key":"481_CR50","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s12325-020-01374-2","volume":"37","author":"S Lalezari","year":"2020","unstructured":"Lalezari S, et al. Comparing physician and patient perspectives on prophylactic treatment with BAY 94\u20139027 for severe haemophilia A: a post hoc analysis. Adv Ther. 2020;37(6):2763\u201376.","journal-title":"Adv Ther"},{"key":"481_CR51","unstructured":"ClinicalTrials.gov. Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation). 17 May 2021. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04085458."},{"issue":"Suppl 2","key":"481_CR52","first-page":"125","volume":"27","author":"PA Holme","year":"2021","unstructured":"Holme PA, et al. Safety and efficacy of BAY 94\u20139027 prophylaxis in patients with severe haemophilia A: interim results of a post-marketing interventional study. Haemophilia. 2021;27(Suppl 2):125.","journal-title":"Haemophilia"},{"key":"481_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044997","volume":"11","author":"M Sanabria","year":"2021","unstructured":"Sanabria M, et al. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A. BMJ Open. 2021;11: e044997.","journal-title":"BMJ Open"},{"key":"481_CR54","unstructured":"ClinicalTrials.gov. Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding (HA-SAFE). 17 May 21. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04461639."},{"key":"481_CR55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.14431","volume":"28","author":"G Di Minno","year":"2022","unstructured":"Di Minno G. A prospective, observational, italian study to assess long-term effectiveness of damoctocog alfa pegol prophylaxis on joint health in adults with haemophilia A (JOIHA) PO024. Haemophilia. 2022;28:25\u2013126.","journal-title":"Haemophilia"},{"key":"481_CR56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.14479","volume":"28","author":"S Campanico","year":"2022","unstructured":"Campanico S, et al. Prophylaxis with damoctocog alfa pegol: real world usage and effectiveness in patients with Hemophilia A of a Portuguese hemophilia Reference Centre PO110. Haemophilia. 2022;28:25\u2013126.","journal-title":"Haemophilia"},{"issue":"S1","key":"481_CR57","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/hae.14715","volume":"29","author":"G Mulders","year":"2023","unstructured":"Mulders G. POSTER ABSTRACTS. Haemophilia. 2023;29(S1):24\u2013202.","journal-title":"Haemophilia"},{"key":"481_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/JBM.S206806","volume":"10","author":"K Batt","year":"2019","unstructured":"Batt K, et al. Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94\u20139027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A. J Blood Med. 2019;10:147\u201359.","journal-title":"J Blood Med."},{"issue":"10","key":"481_CR59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"481_CR60","unstructured":"Phillippo, D., et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. NICE. 2016."},{"issue":"6","key":"481_CR61","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"key":"481_CR62","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2147\/JBM.S321288","volume":"12","author":"P Vashi","year":"2021","unstructured":"Vashi P, et al. Indirect treatment comparison of damoctocog alfa pegol versus turoctocog alfa pegol as prophylactic treatment in patients with hemophilia A. J Blood Med. 2021;12:935\u201343.","journal-title":"J Blood Med."},{"key":"481_CR63","unstructured":"Solms, A., et al. Predicted FVIII consumption of BAY 94-9027 compared with standard- and extended-half-life FVIII products in patients with severe hemophilia A [abstract]. Res Pract Thromb Haemost. 2021;5:423\u2013424."},{"key":"481_CR64","unstructured":"ClinicalTrials.gov. A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood. 2022 [cited 4 May 2022]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05147662."},{"key":"481_CR65","unstructured":"Jonathan Ducore, et al. Alfa-PROTECT: a phase 3, open-label study to evaluate the safety of damoctocog alfa pegol in previously treated children aged 7 to < 12 years with severe hemophilia A in THSNA. 2022."},{"issue":"Suppl 1","key":"481_CR66","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2021-148700","volume":"138","author":"G Young","year":"2021","unstructured":"Young G, et al. PREDICT: A multicenter, prospective, open-label, clinical study using a new risk score approach to assess the most appropriate prophylaxis regimen to reach favorable outcomes in hemophilia A, when switching from standard-half-life products to damoctocog alfa pegol. Blood. 2021;138(Suppl 1):2115.","journal-title":"Blood"},{"key":"481_CR67","unstructured":"ClinicalTrials.gov. Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients Who Have Been Diagnosed With Hemophilia A (HEM-POWR). 2019 [cited 24 Aug 2022]. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03932201."},{"key":"481_CR68","unstructured":"ClinicalTrials.gov. Prophylaxis Regimen for Hemophilia A Patients (PREDICT). 2022 [cited 24 Aug 2022]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05036278."}],"updated-by":[{"DOI":"10.1007\/s40268-024-00494-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000}}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00481-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:09:58Z","timestamp":1735873798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00481-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00481-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"18 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to include the missing graphical abstract file.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40268-024-00494-2","URL":"https:\/\/doi.org\/10.1007\/s40268-024-00494-2","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MTR, SL, GK, GDM, JD, AS, AS, PAH, LHP, KM, MS, and MEM contributed to data selection and interpretation, and were involved in the review design. All authors contributed to the development of the manuscript, reviewed and commented on each draft, and approved the final draft.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have consented to the publication of this review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mark T. Reding has received grants and research support from Bayer and BioMarin; honoraria and consultation fees from Bayer, CSL Behring, Novo Nordisk, Sanofi Genzyme and Takeda; and participates in a company-sponsored speakers bureau for Bayer, CSL Behring, Sanofi Genzyme, and Takeda. Shadan Lalezari has participated in advisory boards for Bayer; and has received honoraria or consultation fees from Bayer, Teva Pharmaceuticals, Takeda, PI Healthcare, Roche, and Pfizer. Gili Kenet has no disclosures to declare. Giovanni Di Minno has participated in speakers bureaus for Bayer, CSL Behring, Novo Nordisk, Pfizer, Sobi and Takeda; and has received consultancy or speakers fees from Bayer, Novo Nordisk, Pfizer, Sanofi Aventis, and Sobi. Jonathan Ducore has received consultancy fees from Bayer and HEMA Biologics and has participated in speakers bureaus for Bayer. Alexander Solms is an employee and shareholder of Bayer AG. Anita Shah is an employee of Bayer and owns Bayer stocks. P\u00e5l\ufeff Andr\u00e9 Holme has received grant\/research support, paid to his institution, from Bayer, Octapharma, Pfizer, Shire, and Sobi, and is a consultant for Bayer, Biomarin, CSL, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and Sobi. Lone H. Poulson has received grant\/research support from Pfizer, and congress support from Bayer, Novo Nordisk, Octapharma, Pfizer, and Sobi. Karina Meijer has no disclosures to declare. Mindy Simpson has received institutional research grants from Bayer, Bioverativ\/Sanofi, Daichii-Sankyo, Octapharma, Novo Nordisk, Baxalta (Shire, Takeda), and Roche (Genentech), and has received honoraria and consultation fees from Bayer, CSL Behring, Octapharma, Novo Nordisk, Roche, and Takeda\/Shire. Maria Elisa Mancuso has received honoraria and consultation fees from Bayer, Bioverativ, Catalyst, CSL Behring, Grifols, Kedrion, Novo Nordisk, Octapharma, Pfizer, Roche, BioMarin, Shire\/Takeda and Sobi, and participates in a company-sponsored speakers bureau for Bayer, CSL Behring, Grifols, Kedrion, Novo Nordisk, Octapharma, Pfizer, Roche, BioMarin, Shire\/Takeda and Sobi.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}